PRODUCT INFORMATION



SR 144528

Item No. 9000491

CAS Registry No.:	192703-06-3	ÇI
Formal Name:	5-(4-chloro-3-methylphenyl)-	
	1-[(4-methylphenyl)	
	methyl]-N-[(1S,2S,4R)-1,3,3-	
	trimethylbicyclo[2.2.1]hept-2-yl]-	$\sum_{i=1}^{n}$
	1H-pyrazole-3-carboxamide	
MF:	C ₂₉ H ₃₄ CIN ₃ O	
FW:	476.1	
Purity:	≥98%	
Supplied as:	A crystalline solid	
Storage:	-20°C	\checkmark
Stability:	≥4 years	\backslash
his and the second state and the second state of the second state		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SR 144528 is supplied as a crystalline solid. A stock solution may be made by dissolving the SR 144528 in the solvent of choice. SR 144528 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of SR 144528 in DMSO is approximately 20 mg/ml and approximately 30 mg/ml in ethanol and DMF.

SR 144528 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SR 144528 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. SR 144528 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SR 144528 is a cannabinoid 2 (CB₂) receptor antagonist ($K_i = 0.6 \text{ nM}$).¹ It is selective for CB₂ over CB₁ receptors in CHO cells expressing the human receptors ($K_i = 437 \text{ nM}$).² SR 144528 reverses CP 55,940-induced inhibition of forskolin-induced adenylyl cyclase activity in CHO cells expressing human CB₂ receptors (EC₅₀ = 10 nM). SR 144528 (0.01 mg/kg) reduces paw swelling in a mouse model of carrageenan-induced paw edema.3

References

- 1. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6(8), 635-664 (1999).
- 2. Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284(2), 644-650 (1998).
- Iwamura, H., Suzuki, H., Ueda, Y., et al. In vitro and in vivo pharmacological characterization of JTE-907, a 3. novel selection ligand for cannabinoid CB₂ receptor. J. Pharmacol. Exp. Ther. 296(2), 420-425 (2001).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/10/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM